Recent progress in nanomedicine for enhanced cancer chemotherapy.
Angiogenesis Inhibitors
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
Drug Carriers
Drug Delivery Systems
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Extracellular Matrix
/ drug effects
Gases
/ therapeutic use
Genetic Therapy
Humans
Immunotherapy
Molecular Targeted Therapy
Nanomedicine
/ methods
Nanoparticles
/ administration & dosage
Neoplasms
/ drug therapy
Organelles
/ drug effects
Particle Size
Photochemotherapy
Photothermal Therapy
Static Electricity
Tissue Distribution
cancer therapy
chemotherapy
combination therapy
nanocarriers
nanomedicine
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
01
2021
accepted:
31
03
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
29
7
2021
Statut:
epublish
Résumé
As one of the most important cancer treatment strategies, conventional chemotherapy has substantial side effects and leads easily to cancer treatment failure. Therefore, exploring and developing more efficient methods to enhance cancer chemotherapy is an urgently important problem that must be solved. With the development of nanotechnology, nanomedicine has showed a good application prospect in improving cancer chemotherapy. In this review, we aim to present a discussion on the significant research progress in nanomedicine for enhanced cancer chemotherapy. First, increased enrichment of drugs in tumor tissues relying on different targeting ligands and promoting tissue penetration are summarized. Second, specific subcellular organelle-targeted chemotherapy is discussed. Next, different combinational strategies to reverse multidrug resistance (MDR) and improve the effective intracellular concentration of therapeutics are discussed. Furthermore, the advantages of combination therapy for cancer treatment are emphasized. Finally, we discuss the major problems facing therapeutic nanomedicine for cancer chemotherapy, and propose possible future directions in this field.
Identifiants
pubmed: 33995663
doi: 10.7150/thno.57828
pii: thnov11p6370
pmc: PMC8120226
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antineoplastic Agents
0
Drug Carriers
0
Gases
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6370-6392Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Curr Med Chem. 2012;19(22):3794-804
pubmed: 22725698
Adv Mater. 2019 Dec;31(51):e1904197
pubmed: 31595562
ACS Appl Mater Interfaces. 2016 Jun 8;8(22):13804-11
pubmed: 27213922
Biomaterials. 2020 May;241:119901
pubmed: 32109706
Cancer Chemother Pharmacol. 2011 Oct;68(4):945-50
pubmed: 21301848
Adv Sci (Weinh). 2020 Oct 12;7(22):2002030
pubmed: 33240763
ACS Nano. 2020 Dec 22;14(12):17405-17418
pubmed: 33202141
Nano Lett. 2019 Feb 13;19(2):997-1008
pubmed: 30676760
Acta Pharmacol Sin. 2016 Aug;37(8):1110-20
pubmed: 27292613
Adv Mater. 2019 Jan;31(3):e1802725
pubmed: 30260521
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Small. 2020 Aug;16(31):e2000897
pubmed: 32537936
ACS Nano. 2016 Jul 26;10(7):6753-61
pubmed: 27244096
Nat Rev Clin Oncol. 2016 Dec;13(12):750-765
pubmed: 27531700
Biomaterials. 2017 Jan;112:234-247
pubmed: 27768976
Nanoscale. 2020 Oct 29;12(41):21234-21247
pubmed: 33063070
Adv Mater. 2016 Sep;28(34):7340-64
pubmed: 27255214
ACS Nano. 2014 May 27;8(5):5105-15
pubmed: 24742221
J Control Release. 2017 Oct 10;263:223-230
pubmed: 28034787
ACS Macro Lett. 2019 Dec 17;8(12):1552-1558
pubmed: 35619381
Nat Rev Drug Discov. 2010 Jun;9(6):447-64
pubmed: 20467424
Nano Lett. 2016 May 11;16(5):3268-77
pubmed: 27057591
Small. 2020 Nov;16(45):e2001805
pubmed: 33079449
Adv Mater. 2020 Mar;32(12):e1907568
pubmed: 32053267
Cell Res. 2020 Feb;30(2):146-162
pubmed: 31949285
Adv Mater. 2020 Apr;32(16):e1906745
pubmed: 32105374
Small. 2020 Sep;16(35):e2001177
pubmed: 32762022
Theranostics. 2020 May 17;10(15):6629-6637
pubmed: 32550894
Int J Pharm. 2017 Jun 30;526(1-2):474-495
pubmed: 28501439
J Control Release. 2020 Jun 10;322:157-169
pubmed: 32169533
Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4164-9
pubmed: 27035960
ACS Nano. 2020 Nov 24;14(11):14831-14845
pubmed: 33084319
ACS Nano. 2016 Jun 28;10(6):5643-55
pubmed: 27093466
ACS Nano. 2019 Aug 27;13(8):9386-9396
pubmed: 31375027
Am J Surg. 1963 May;105:574-8
pubmed: 13947966
Biomaterials. 2010 Mar;31(7):1787-97
pubmed: 19889452
Nanoscale Horiz. 2021 Feb 1;6(2):120-131
pubmed: 33206735
J Control Release. 2017 Apr 10;251:49-67
pubmed: 28232226
Acta Biomater. 2019 Dec;100:365-377
pubmed: 31586724
Chem Soc Rev. 2015 Dec 21;44(24):8836-47
pubmed: 26595684
Adv Healthc Mater. 2016 Nov;5(22):2872-2881
pubmed: 27676694
Colloids Surf B Biointerfaces. 2020 May;189:110810
pubmed: 32014651
Adv Sci (Weinh). 2020 Sep 06;7(20):2001853
pubmed: 33101874
Adv Healthc Mater. 2018 Dec;7(24):e1801094
pubmed: 30565900
Nanoscale. 2020 Jul 16;12(27):14739-14750
pubmed: 32626854
ACS Nano. 2019 Jan 22;13(1):274-283
pubmed: 30566319
Small. 2018 Mar;14(12):e1702994
pubmed: 29205795
ACS Nano. 2018 Dec 26;12(12):12380-12392
pubmed: 30495919
ACS Appl Mater Interfaces. 2020 Sep 9;12(36):40085-40093
pubmed: 32791825
Biomater Sci. 2016 Feb;4(2):338-45
pubmed: 26623461
Adv Mater. 2020 Sep;32(38):e2002380
pubmed: 33252171
Adv Sci (Weinh). 2020 Nov 05;7(24):2001191
pubmed: 33344115
Biomaterials. 2016 Feb;80:169-178
pubmed: 26708642
Theranostics. 2019 Jan 1;9(2):337-354
pubmed: 30809278
J Mater Chem B. 2018 Dec 28;6(48):8137-8147
pubmed: 32254933
Nanomedicine. 2015 Oct;11(7):1841-50
pubmed: 26115641
Nat Rev Mater. 2017;2:
pubmed: 29075517
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1866-79
pubmed: 24120656
J Biol Chem. 1995 Sep 8;270(36):21129-36
pubmed: 7545665
ACS Appl Mater Interfaces. 2019 Jan 9;11(1):255-268
pubmed: 30561993
Biomaterials. 2016 Jan;76:115-32
pubmed: 26520043
Biomaterials. 2016 Jan;77:227-34
pubmed: 26606448
Nanoscale. 2015 Oct 21;7(39):16470-80
pubmed: 26395038
J Am Chem Soc. 2020 Feb 26;142(8):3939-3946
pubmed: 31968933
ACS Appl Mater Interfaces. 2018 Aug 15;10(32):26870-26881
pubmed: 30039695
Biomaterials. 2000 Jan;21(1):1-7
pubmed: 10619673
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7444-9
pubmed: 12032302
Small. 2020 Nov;16(44):e2004172
pubmed: 33030305
J Control Release. 2019 May 10;301:76-109
pubmed: 30890445
J Control Release. 2015 Nov 10;217:102-12
pubmed: 26297207
Adv Mater. 2017 Feb;29(5):
pubmed: 27882622
Biomaterials. 2014 Feb;35(7):2391-400
pubmed: 24360574
ACS Nano. 2020 Aug 25;14(8):9780-9795
pubmed: 32806062
Nano Lett. 2020 Nov 11;20(11):8102-8111
pubmed: 33064007
Nanomicro Lett. 2020 Oct 27;13(1):6
pubmed: 34138195
Adv Sci (Weinh). 2019 Jan 18;6(5):1801986
pubmed: 30886808
J Clin Pharmacol. 2006 Jul;46(7):727-37
pubmed: 16809798
Acta Biomater. 2019 May;90:314-323
pubmed: 30981751
Adv Mater. 2018 Mar;30(12):e1704007
pubmed: 29356212
Biomater Sci. 2019 Nov 1;7(11):4615-4623
pubmed: 31441464
Chem Sci. 2016 May 1;7(5):3017-3024
pubmed: 29997791
Nanoscale. 2019 Mar 21;11(12):5474-5488
pubmed: 30855625
Adv Mater. 2018 Dec;30(49):e1801964
pubmed: 30066474
ACS Appl Mater Interfaces. 2020 Apr 22;12(16):18273-18291
pubmed: 32223148
ACS Nano. 2016 Nov 22;10(11):10404-10417
pubmed: 27934087
Biomaterials. 2012 Mar;33(7):2310-20
pubmed: 22166223
Adv Mater. 2019 Dec;31(52):e1904997
pubmed: 31721331
Biomaterials. 2018 Jul;171:178-197
pubmed: 29698868
Biomaterials. 2014 Jan;35(4):1215-26
pubmed: 24231414
Adv Sci (Weinh). 2020 Jul 29;7(18):2000515
pubmed: 32999828
ACS Appl Mater Interfaces. 2016 Mar 9;8(9):5833-46
pubmed: 26889562
Nano Lett. 2015 Jan 14;15(1):457-63
pubmed: 25479133
Theranostics. 2020 Jun 22;10(17):7889-7905
pubmed: 32685027
Eur J Pharm Sci. 2009 Jun 28;37(3-4):300-5
pubmed: 19491019
Adv Ther. 2019 May;36(5):1150-1163
pubmed: 30879251
Angew Chem Int Ed Engl. 2017 Mar 1;56(10):2588-2593
pubmed: 28140504
J Control Release. 2017 Mar 10;249:63-73
pubmed: 28122204
J Am Chem Soc. 2013 Oct 16;135(41):15501-7
pubmed: 24028269
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
Biomacromolecules. 2017 May 8;18(5):1449-1459
pubmed: 28328191
Biomaterials. 2020 Jul;245:119983
pubmed: 32229333
Cancer Res Treat. 2018 Jan;50(1):195-203
pubmed: 28324920
Biophys J. 2010 Sep 8;99(5):1342-9
pubmed: 20816045
Nano Lett. 2020 Nov 11;20(11):8141-8150
pubmed: 33172280
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nanomicro Lett. 2020 Jul 5;12(1):142
pubmed: 34138136
Adv Healthc Mater. 2014 May;3(5):752-60
pubmed: 24574261
Adv Healthc Mater. 2018 Apr;7(7):e1700974
pubmed: 29334189
Adv Sci (Weinh). 2019 Dec 12;7(3):1901293
pubmed: 32042550
Adv Drug Deliv Rev. 2016 Mar 1;98:3-18
pubmed: 26546465
ACS Nano. 2018 Oct 23;12(10):10061-10074
pubmed: 30222314
Chem Commun (Camb). 2015 Feb 18;51(14):2756-67
pubmed: 26829150
Biomaterials. 2018 Feb;154:169-181
pubmed: 29128845
ACS Nano. 2015 Oct 27;9(10):9517-27
pubmed: 26301492
Small. 2020 Oct;16(41):e2002733
pubmed: 32945130
Angew Chem Int Ed Engl. 2018 Apr 23;57(18):4902-4906
pubmed: 29488312
Adv Sci (Weinh). 2020 Nov 13;7(24):2003036
pubmed: 33344142
Nat Biotechnol. 2016 Apr;34(4):414-8
pubmed: 26974511
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Adv Mater. 2020 Dec;32(50):e2004385
pubmed: 33164250
Eur J Pharm Biopharm. 2017 Jun;115:243-256
pubmed: 28323111
J Control Release. 2015 Aug 10;211:163-70
pubmed: 26070245
Nat Commun. 2016 Oct 21;7:13193
pubmed: 27767031
Science. 2011 Jul 1;333(6038):90-3
pubmed: 21659568
ACS Appl Mater Interfaces. 2014 Jun 11;6(11):8549-59
pubmed: 24804870
ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39493-39502
pubmed: 31576732
J Colloid Interface Sci. 2021 Apr;587:358-366
pubmed: 33360905
Adv Mater. 2015 Nov 4;27(41):6450-6
pubmed: 26401989
Int J Nanomedicine. 2020 Jun 22;15:4431-4440
pubmed: 32606687
Small. 2020 Feb;16(7):e1906832
pubmed: 31990457
Adv Mater. 2020 Feb;32(6):e1906024
pubmed: 31834662
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3850-4
pubmed: 27001839
PLoS One. 2012;7(4):e34833
pubmed: 22558101
Int J Pharm. 2017 Oct 30;532(1):249-268
pubmed: 28882486
ACS Appl Mater Interfaces. 2020 May 6;12(18):20271-20280
pubmed: 32283924
Cancer Res. 2000 May 1;60(9):2497-503
pubmed: 10811131
ACS Nano. 2016 Mar 22;10(3):3496-508
pubmed: 26866752
J Control Release. 2020 Dec 10;328:617-630
pubmed: 32976902
Biomaterials. 2017 Jun;129:83-97
pubmed: 28329693
Biomaterials. 2018 Dec;185:301-309
pubmed: 30265899
ACS Nano. 2020 Jul 28;14(7):8135-8148
pubmed: 32479062
Int J Pharm. 2012 Apr 15;426(1-2):193-201
pubmed: 22274587
ACS Nano. 2017 May 23;11(5):4463-4474
pubmed: 28362496
Adv Healthc Mater. 2017 Feb;6(3):
pubmed: 27943651
Adv Drug Deliv Rev. 2019 Apr;144:57-77
pubmed: 31400350
J Control Release. 2019 Nov 10;313:42-53
pubmed: 31629039
ACS Nano. 2017 Feb 28;11(2):2227-2238
pubmed: 28165223